Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Metacrine, Inc.    MTCR

METACRINE, INC.

(MTCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

METACRINE, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
09/18/2020 | 06:26pm EDT

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Amendment and Restatement of Certificate of Incorporation

On September 18, 2020, Metacrine, Inc. (the "Company") filed an Amended and Restated Certificate of Incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware, in connection with the closing of the initial public offering of shares of common stock of the Company on September 18, 2020 (the "IPO"). The Company's board of directors and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.

Amendment and Restatement of Bylaws

Effective as of September 18, 2020, the Company adopted Amended and Restated Bylaws (the "Restated Bylaws") in connection with the closing of the IPO. The Company's board of directors and stockholders previously approved the Restated Bylaws to be effective upon the closing of the IPO.

The foregoing descriptions of the Restated Certificate and Restated Bylaws are qualified in their entirety by reference to the full text of the Restated Certificate and Restated Bylaws, which are filed as Exhibits 3.1 and 3.2 hereto, respectively, and are incorporated herein by reference.

Item 8.01. Other Events.

On September 18, 2020, the Company closed its IPO of 6,540,000 shares of its common stock at a price to the public of $13.00 per share. The gross proceeds to the Company from the IPO were approximately $85.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, the Company has granted the underwriters of the IPO a 30-day option to purchase up to an additional 981,000 shares of its common stock.

Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.



 Exhibit
   No.     Description

 3.1         Amended and Restated Certificate of Incorporation of the Company.

 3.2         Amended and Restated Bylaws of the Company.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about METACRINE, INC.
10/01METACRINE : to Present New Data from MET409 Program in NASH at AASLD's The Liver..
AQ
10/01Metacrine to Present New Data from MET409 Program in NASH at AASLD's The Live..
GL
09/18METACRINE, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Yea..
AQ
More news